Concomitant medications and circulating tumor cells: friends or foes?
Breast cancer
circulating tumor cells
concomitant medications
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
05
2022
revised:
08
10
2022
accepted:
25
11
2022
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
The use of concomitant medications by patients with cancer is observed almost globally; however, little attention has been paid to this topic in the medical literature. Most clinical studies do not describe the type and duration of drugs used at the time of inclusion and during treatment or how these drugs may affect the experimental and/or standard therapy. Even less information has been published on the potential interaction between concomitant medications and tumor biomarkers. However, we do know that concomitant drugs can complicate cancer clinical trials and biomarker development, thus contributing to their interaction, leading to side effects, and resulting in suboptimal adherence to anticancer treatment. On the basis of these premises and moving from the study by Jurisova
Identifiants
pubmed: 37065865
doi: 10.20517/cdr.2022.68
pmc: PMC10099593
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-34Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
Both authors declared that there are no conflicts of interest.
Références
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Nanomedicine. 2020 Feb;24:102106
pubmed: 31666201
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
pubmed: 15501967
Oncol Lett. 2016 Sep;12(3):1711-1716
pubmed: 27588120
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003475
Breast Cancer Res Treat. 2011 Sep;129(2):549-56
pubmed: 21479924
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Science. 2013 Feb 1;339(6119):580-4
pubmed: 23372014
J Control Release. 2016 Apr 28;228:38-47
pubmed: 26921521
J Cancer. 2013 Aug 10;4(7):549-56
pubmed: 23983819
Ann Oncol. 2011 Aug;22(8):1929-30
pubmed: 21633048
Int J Biol Markers. 2015 Nov 11;30(4):e429-33
pubmed: 26349664
J Cancer. 2012;3:345-53
pubmed: 22962561
Cancer Discov. 2021 Apr;11(4):858-873
pubmed: 33811121
Nat Rev Cancer. 2019 Oct;19(10):553-567
pubmed: 31455893
Cardiovasc Res. 2003 Apr 1;58(1):203-12
pubmed: 12667963
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Cancer Metastasis Rev. 2012 Dec;31(3-4):673-87
pubmed: 22733306
Front Pharmacol. 2022 Mar 25;13:820806
pubmed: 35401176
Biomed Rep. 2014 May;2(3):331-334
pubmed: 24748969
Cancer Drug Resist. 2020 Mar 19;3(1):98-109
pubmed: 35582045
Ann Oncol. 2009 Dec;20(12):1907-12
pubmed: 19713244
Breast Cancer Res. 2018 Nov 20;20(1):141
pubmed: 30458879